Picard Medical / SynCardia Unveil Next-Generation Emperor Total Artificial Heart at ACC.26

Key Highlights for Investors

• Picard Medical, Inc. (NYSE American: PMI) announces new preclinical data on its Emperor Total Artificial Heart at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.26).
• Fully Implantable, Autoregulating Artificial Heart Platform: The Emperor Total Artificial Heart aims to preserve the proven hemodynamic performance of the FDA-approved SynCardia Total Artificial Heart while offering fully implantable operation.
• Poster Presentation Details:
  • Title: “THE EMPEROR TOTAL ARTIFICIAL HEART: A FULLY IMPLANTABLE, AUTOREGULATING SOLUTION FOR HEART FAILURE”
  • Date: Sunday, March 29, 2026 | 11:00 a.m. – 12:00 p.m.
  • Location: Posters, Hall E
  • Presenter: Duffy Elmer, Engineering Project Manager, SynCardia LLC
• Conference Exhibit: SynCardia will also exhibit at booth #2554 throughout ACC.26, providing opportunities for clinicians, researchers, and investors to engage with company representatives and learn more about both current and next-generation technologies.

Detailed Article for Investors

Picard Medical, Inc., the parent company of SynCardia Systems LLC, has announced a significant milestone in its artificial heart technology portfolio. The company will present new preclinical data on its next-generation Emperor Total Artificial Heart platform at the upcoming American College of Cardiology’s Annual Scientific Session & Expo (ACC.26) in New Orleans, scheduled from March 28 to March 30, 2026.

SynCardia, based in Tucson, Arizona, is renowned for having the world’s first and only commercially available total artificial heart approved by both the U.S. FDA and Health Canada. The SynCardia Total Artificial Heart (STAH) has been implanted more than 2,100 times across 27 countries, making it the most widely used and studied artificial heart globally.

The newly developed Emperor Total Artificial Heart is designed to be a fully implantable, electromechanical artificial heart system with physiologic autoregulation. This innovation seeks to preserve the proven hemodynamic performance of the SynCardia STAH while enabling long-term, fully implantable support. According to Duffy Elmer, Engineering Project Manager at SynCardia LLC, “The Emperor Total Artificial Heart represents the next evolution in total artificial heart therapy. The system is being designed to combine a fully implantable architecture with physiologic autoregulation in order to preserve the proven hemodynamic performance of the SynCardia Total Artificial Heart while enabling fully implantable long-term support. By building on the reliability and clinical experience of the SynCardia platform, the Emperor program aims to expand treatment options and improve mobility and quality of life for patients with advanced heart failure.”

At ACC.26, SynCardia’s clinical and engineering teams will be available to discuss the Emperor platform’s design, development progress, and future clinical directions. Conference attendees can also learn about the clinical use of the FDA-approved SynCardia Total Artificial Heart as a bridge to transplant for patients with advanced biventricular heart failure.

Potential Impact on Shareholders and Share Value

• Innovation and Market Leadership: The unveiling of the Emperor Total Artificial Heart demonstrates Picard Medical’s commitment to innovation and leadership in the artificial heart market. As the only company with an FDA- and Health Canada-approved total artificial heart, further advancements could strengthen its competitive position.
• Expansion of Treatment Options: The fully implantable design and autoregulation features of the Emperor platform may expand patient eligibility, improve quality of life, and potentially increase the addressable market for Picard Medical.
• Commercial and Clinical Opportunities: Progress towards a fully implantable artificial heart may attract greater clinical adoption, strategic partnerships, and investor interest, potentially impacting share value.
• Early Data and Development Milestone: The presentation of early preclinical data is a material event, signaling advancement towards clinical trials and eventual commercialization. If successful, this could be a significant catalyst for the stock.

Risks and Forward-Looking Statements

As noted by Picard Medical, these developments are subject to risks and uncertainties. Forward-looking statements regarding the Emperor Total Artificial Heart’s development, clinical adoption, and commercial potential may not materialize as expected and are influenced by numerous factors, including regulatory approval, clinical trial outcomes, market acceptance, and competitive dynamics. Investors should refer to the company’s filings with the SEC for a full discussion of risk factors.

Contact Information

Investors:
Eric Ribner, Managing Director, LifeSci Advisors LLC
[email protected]
Picard Medical, Inc./SynCardia Systems, LLC
[email protected]
General/Media:
Brittany Lanza
[email protected]

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Investors should review official filings and consult with financial advisors before making investment decisions.

View Picard Medical, Inc. Historical chart here